malathion · Taro · NDA 018613
Ovide
Earliest generic entry, as listed
1 Feb 2027
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7560445.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7560445 | substance, product, use U-986 | 1 Feb 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Enters 12-month window basis: patent · 018613-0011 Feb 2027
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 018613 · 001 · RLD · discontinued | lotion, topical | 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1 Feb 2027 |
Expired or delisted (1)
- US 7977324 · product · 14 Aug 2026